Clinical, laboratory, molecular, and treatment characteristics and outcome of 28 patients with advSM, stratified by KIT D816V EAB reduction at month 6 (≥25% vs <25%)
| Variables . | All patients . | Decrease of KIT D816V . | P* . | |
|---|---|---|---|---|
| EAB ≥25% . | EAB <25% . | |||
| No. of patients (n) | 28 | 17 | 11 | |
| Age in y, median (range) | 65 (48-76) | 68 (48-76) | 63 (55-75) | NS |
| Males, n (%) | 19 (68) | 10 (59) | 9 (82) | NS |
| Diagnosis | ||||
| ASM, n (%) | 3 (11) | 3 (18) | 0 | |
| MCL, n (%) | 2 (7) | 2 (12) | 0 | |
| SM-AHN | 23 (82) | 12 (71) | 11 (100) | NS |
| SM, n (%) | 19 (83) | 10 (83) | 9 (82) | |
| MCL, n (%) | 4 (17) | 2 (17) | 2 (18) | |
| Any response according Valent criteria | 15 (54) | 13 (76) | 2 (18) | .006 |
| Molecular profile | ||||
| S/A/Rpos, n (%) | 18 (65) | 9 (53) | 9 (82) | NS |
| Other mutation, n (%) | 6 (21) | 4 (24) | 2 (18) | |
| No mutation, n (%) | 4 (14) | 4 (24) | 0 | |
| Loss of KIT response†, n (%) | 4 (24) | — | ||
| S/A/Rpos, n (%) | 4 (24) | — | ||
| Median time on midostaurin, mo (range) | 19 (6-88) | 25 (6-88) | 9 (7-35) | .01 |
| Number of patients on midostaurin at time of reporting, n (%) | 10 (36) | 10 (59) | 0 | .002 |
| Outcome | ||||
| Median OS, mo (95% CI) | 45 (17-73) | NR | 27 (7-51) | .0004‡ |
| Death, n (%) | 14 (50) | 4 (24) | 10 (91) | |
| Variables . | All patients . | Decrease of KIT D816V . | P* . | |
|---|---|---|---|---|
| EAB ≥25% . | EAB <25% . | |||
| No. of patients (n) | 28 | 17 | 11 | |
| Age in y, median (range) | 65 (48-76) | 68 (48-76) | 63 (55-75) | NS |
| Males, n (%) | 19 (68) | 10 (59) | 9 (82) | NS |
| Diagnosis | ||||
| ASM, n (%) | 3 (11) | 3 (18) | 0 | |
| MCL, n (%) | 2 (7) | 2 (12) | 0 | |
| SM-AHN | 23 (82) | 12 (71) | 11 (100) | NS |
| SM, n (%) | 19 (83) | 10 (83) | 9 (82) | |
| MCL, n (%) | 4 (17) | 2 (17) | 2 (18) | |
| Any response according Valent criteria | 15 (54) | 13 (76) | 2 (18) | .006 |
| Molecular profile | ||||
| S/A/Rpos, n (%) | 18 (65) | 9 (53) | 9 (82) | NS |
| Other mutation, n (%) | 6 (21) | 4 (24) | 2 (18) | |
| No mutation, n (%) | 4 (14) | 4 (24) | 0 | |
| Loss of KIT response†, n (%) | 4 (24) | — | ||
| S/A/Rpos, n (%) | 4 (24) | — | ||
| Median time on midostaurin, mo (range) | 19 (6-88) | 25 (6-88) | 9 (7-35) | .01 |
| Number of patients on midostaurin at time of reporting, n (%) | 10 (36) | 10 (59) | 0 | .002 |
| Outcome | ||||
| Median OS, mo (95% CI) | 45 (17-73) | NR | 27 (7-51) | .0004‡ |
| Death, n (%) | 14 (50) | 4 (24) | 10 (91) | |